Life Science Investing Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Life Science Investing Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
Life Science Investing Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
